Lifecore Biomedical (LFCR) to Release Earnings on Thursday

Lifecore Biomedical (NASDAQ:LFCR) is expected to announce its earnings results on Thursday, April 3rd. Analysts expect the company to announce earnings of ($0.14) per share and revenue of $33.23 million for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Lifecore Biomedical (NASDAQ:LFCR) last posted its quarterly earnings results on Thursday, January 2nd. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.02. Lifecore Biomedical had a negative return on equity of 315.23% and a negative net margin of 12.52%. On average, analysts expect Lifecore Biomedical to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Lifecore Biomedical Price Performance

Shares of LFCR opened at $6.83 on Friday. The firm has a market capitalization of $252.88 million, a price-to-earnings ratio of -12.20 and a beta of 0.96. The firm’s fifty day simple moving average is $6.14 and its 200-day simple moving average is $6.17. Lifecore Biomedical has a twelve month low of $3.68 and a twelve month high of $7.99. The company has a current ratio of 2.32, a quick ratio of 1.21 and a debt-to-equity ratio of 9.21.

Wall Street Analysts Forecast Growth

Separately, Stephens restated an “equal weight” rating and issued a $6.00 price objective on shares of Lifecore Biomedical in a research note on Friday, January 3rd.

Insider Buying and Selling at Lifecore Biomedical

In other news, CEO Paul Josephs acquired 17,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 8th. The stock was purchased at an average cost of $5.74 per share, with a total value of $97,580.00. Following the purchase, the chief executive officer now directly owns 559,717 shares of the company’s stock, valued at approximately $3,212,775.58. This trade represents a 3.13 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. 32.20% of the stock is owned by corporate insiders.

About Lifecore Biomedical

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.